December 2016
-
Novartis has announced that its Ultibro Breezhaler indacaterol/glycopyrronium DPI (QVA149) has gotten a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of COPD. The company filed an… Read more . . .
-
Pulmatrix has initiated a Phase 1B study of its PUR0200, an inhaled LAMA for the treatment of COPD, the company says. PUR0200 is a lactose-free formulation created using the company’s iSPERSE particle engineering technology. Pulmatrix… Read more . . .
-
Mylan has announced that the United States District Court for the Northern District of West Virginia granted a Mylan motion for partial summary judgment and found that Teva’s generic formoterol fumarate inhalation solution infringes US… Read more . . .
-
Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx’s Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from… Read more . . .
-
MDI component manufacturer Presspart has hired Sameer Kunte as its new Customer Services Manager for India, the company said. Kunte has extensive experience with OINDP device development and has worked previously for 3M, Dr. Reddy’s,… Read more . . .
-
The final article in a 3-part series . . . Read more Read more . . .
-
Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product. The company… Read more . . .
-
GlaxoSmithKline and Theravance have withdrawn the application for their fluticasone furoate/vilanterol DPI for the treatment of COPD from the Japanese New Drug Application (JNDA) for the drug, the companies say. Review of the JNDA, which… Read more . . .
-
GlaxoSmithKline has announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved for the treatment of COPD in Canada. GlaxoSmithKline Inc. President Paul Lirette said, “For over forty years, GlaxoSmithKline has been at the… Read more . . .
-
Inhaler testing automation supplier Astech Projects is celebrating its 18th anniversary on July 18, 2013 by offering a free consultation and proposal for a laboratory automation system. The company manufactures semi- to fully-automated dose content… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland